We are live on
!
Find out more
SCM
Sarissa Capital Management Portfolio holdings
AUM
$158M
1-Year Est. Return
103.7%
This Fund
S&P 500
This Quarter
Est. Return
-16.8%
1 Year Est. Return
+103.7%
3 Year Est. Return
+58.62%
5 Year Est. Return
+92.85%
10 Year Est. Return
+667.68%
AUM
$784M
AUM Growth
-$421M
(-35%)
Cap. Flow
-$177M
Cap. Flow
% of AUM
-22.62%
Top 10 Holdings %
Top 10 Hldgs %
99.98%
Holding
13
New
1
Increased
4
Reduced
–
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alkermes
ALKS
|
+$60.5M |
| 2 |
Jazz Pharmaceuticals
JAZZ
|
+$41.6M |
| 3 |
Ironwood Pharmaceuticals
IRWD
|
+$37.8M |
| 4 |
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
|
+$26.5M |
| 5 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$13.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
MDCO
Medicines Co
MDCO
|
+$357M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Biogen
BIIB
$30B
| $203M | 25.95% |
643,000
| – | – |
|
|
2
Ironwood Pharmaceuticals
IRWD
$696M
| $136M | 17.41% |
13,525,000
+3,218,000
| +31% | +$37.8M |
|
|
3
Alkermes
ALKS
$8.22B
| $104M | 13.23% |
7,193,000
+3,388,000
| +89% | +$60.5M |
|
|
AGN
4
DELISTED
Allergan plc
AGN
| $82.8M | 10.56% |
467,500
| – | – |
|
|
5
Jazz Pharmaceuticals
JAZZ
$15.9B
| $76.3M | 9.73% |
765,000
+321,500
| +72% | +$41.6M |
|
6
Innoviva
INVA
$1.55B
| $73.4M | 9.36% |
6,242,000
| – | – |
|
|
ICPT
7
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $72.7M | 9.28% |
1,155,000
+295,000
| +34% | +$26.5M |
|
|
MRSN
8
DELISTED
Mersana Therapeutics
MRSN
| $21.9M | 2.79% |
150,000
| – | – |
|
|
ALXN
9
DELISTED
Alexion Pharmaceuticals
ALXN
| $12.1M | 1.55% |
+135,000
| New | +$13.2M |
|
|
RGLS
10
DELISTED
Regulus Therapeutics
RGLS
| $853K | 0.11% |
185,185
| – | – |
|
11
AbbVie
ABBV
$443B
| $76K | 0.01% |
1,000
| – | – |
|
|
MRTX
12
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $76K | 0.01% |
1,000
| – | – |
|
|
MDCO
13
DELISTED
Medicines Co
MDCO
| – | – |
-4,202,000
| Closed | -$357M |
|
Similar funds
4A
DAM
PCP
CF
HEM
SF
AC
EP
Sarissa Capital Management's Q1 2020 Portfolio in Review
As of Q1 2020, Sarissa Capital Management held 13 positions worth $784M, down 35% from $1.2B the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Sarissa Capital Management withdrew a net $177M in Q1 2020, closing 1 position. Its most notable exit was Medicines Co, an estimated $357M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 65% a quarter earlier.
Against the trend, Sarissa Capital Management opened a new position in Alexion Pharmaceuticals worth $12.1M.
- Sarissa Capital Management's largest Q1 2020 buy was Alexion Pharmaceuticals: 135,000 shares worth $12.1M.
- Sarissa Capital Management added most to Alkermes in Q1 2020, an estimated $60.5M increase.
- Sarissa Capital Management fully exited Medicines Co in Q1 2020, selling an estimated $357M.
- Sarissa Capital Management's ten largest holdings make up 100% of its $784M portfolio in Q1 2020.
- Sarissa Capital Management opened 1 new position and closed 1 in Q1 2020.
- Sarissa Capital Management's portfolio value fell 35% quarter-over-quarter to $784M.
Based on Sarissa Capital Management's 13F filing for Q1 2020, filed 15 May 2020.